Search the Newsreel

FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease

The FDA has approved Lantheus Holdings Inc.'s TAUKLARIFY (florquinitau F 18 injection), a tau imaging agent for Alzheimer's disease. This radiodiagnostic agent is intended for brain PET scans in adults with cognitive impairment to identify tau neurofibrillary tangle pathology. The approval is based on …

Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s

[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer’s disease through positron emission tomography (PET). Specifically, the approval allows the …

US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

The U.S. FDA has approved Lantheus Holdings' radioactive agent, Tauklarify, for use in brain scans to assess Alzheimer's disease by making abnormal tau protein deposits visible. This approval was based on two studies involving over 500 participants. While the tau-imaging market is currently dominated …

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

Lantheus Holdings, Inc. BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and …

FDA approves Lantheus brain scan to identify tau in Alzheimer’s

Lantheus has received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a PET imaging agent used to detect tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. The approval is based on two blinded read studies demonstrating high diagnostic …

Farallon group (LNTH) discloses 5.58M-share, 8.6% position in Lantheus

Farallon Capital Management, L.L.C. and its related funds have reported a beneficial ownership of 5,583,479 shares of Lantheus Holdings, Inc. common stock, which represents 8.6% of the outstanding class as of June 30, 2026. This disclosure was made via an amended Schedule 13G filing. …

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Hold" from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $108.11. The company recently exceeded earnings and revenue expectations, reporting $1.55 EPS and $388.18 million in revenue. Institutional investors hold a significant 99.06% of the …

Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH

Pacer Advisors Inc. significantly reduced its stake in Lantheus Holdings, Inc. by 97.0% in the first quarter, selling 247,589 shares and retaining 7,704 shares valued at $584,000. Despite this, other institutional investors have recently modified their holdings, and 99.06% of the stock is still …

Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?

Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) for US$102.50 in cash per share plus contingent value rights up to US$12.00 per share, with the deal expected to close in the first half of 2027. The article discusses whether the remaining upside …

Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH

Empowered Funds LLC initiated a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by purchasing 11,979 shares valued at approximately $909,000. This comes as Lantheus exceeded quarterly earnings expectations, reporting $1.55 EPS against a $1.30 consensus, though analyst sentiment has softened with several downgrades to …

Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.'s 2nd Largest Position

Reinhart Partners LLC. has increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2%, making it their second-largest holding and comprising 4.1% of their portfolio. Despite this, analyst sentiment has softened, leading to several downgrades to "Hold" and a consensus price target of $108.11. …

Lantheus (LNTH) Stock Shrugs Off Solid Profit As Margin Questions Linger

Lantheus Holdings (LNTH) stock saw a minimal price change despite solid Q2 earnings, with revenue meeting expectations and EPS remaining flat year-over-year. Investors are weighing the company's strong trailing P/E against questions about future growth pillars like Alzheimer’s diagnostics and operating leverage, especially after …

Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential additional payments of up to $12.00 per share via Contingent …

Lantheus Holdings Inc earnings beat by $0.26, revenue topped estimates

Lantheus Holdings Inc (LNTH) reported strong second-quarter results, beating analyst expectations for both EPS and revenue. The company announced an EPS of $1.55 against an estimate of $1.29, and revenue of $388.2 million, surpassing the consensus of $362.32 million. LNTH's stock has shown significant …

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ:LNTH) reported strong Q2 CY2026 results, exceeding Wall Street expectations with revenue of $388.2 million and non-GAAP EPS of $1.55. Despite impressive five-year revenue and EPS growth, recent performance shows a slowdown, with analysts projecting a revenue decline for the next 12 …

Earnings Flash (LNTH) Lantheus Holdings, Inc. Reports Q2 Revenue $388.2M, vs. FactSet Est of $363.2M

Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q2 Adjusted EPS $1.55 per Share, vs. FactSet Est of $1.30

Lantheus Holdings, Inc. (LNTH) reported Q2 adjusted EPS of $1.55 per share, surpassing the FactSet estimate of $1.30. The company also announced its Q2 revenue of $388.2 million, exceeding the FactSet estimate of $363.2 million. Additionally, Lantheus suspended its previously issued full-year 2026 financial …

Lantheus Reports Second Quarter 2026 Financial Results

Lantheus Holdings, Inc. Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the …

Lantheus Holdings: Q2 Earnings Snapshot

Lantheus Holdings Inc. reported strong second-quarter earnings, surpassing Wall Street expectations. The diagnostic imaging company posted a profit of $1.11 per share and adjusted earnings of $1.55 per share, exceeding analyst estimates of $1.33. Revenue for the quarter also beat forecasts, coming in at …

Lantheus' Q2 Adjusted Earnings Fall, Revenue Rises

Lantheus (LNTH) reported a decrease in its Q2 adjusted earnings per diluted share to $1.55, although the company saw an increase in its revenue for the same quarter. The article notes that further details are available for premium subscribers.

Earnings To Watch: Lantheus (LNTH) Reports Q2 Results Tomorrow

Curium to acquire Lantheus in all-cash deal worth up to $8bn

CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per …

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH) following its recently announced transaction with Curium, questioning if the deal provides a fair price for public shareholders. Lantheus shareholders are set to receive $102.50 per share in cash, plus Contingent Value Rights potentially worth …

Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)

Monteverde & Associates PC, a class action law firm, has announced an investigation into Lantheus Holdings, Inc. (NASDAQ: LNTH) following its proposed sale to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential contingent value rights of …

Lantheus Stock Is Gaining Monday: What's Going On? - Lantheus Holdings (NASDAQ:LNTH)

Global investment firm CapVest Partners' portfolio company Curium is set to acquire Lantheus Holdings (NASDAQ:LNTH) in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, plus contingent value rights potentially adding $12.00 per share, totaling up …

Curium deepens radiopharma heft with up to $8 billion deal for Lantheus

By Kamal Choudhury and Kunal Das Aug 3 (Reuters) - Radiopharmaceutical company Curium has agreed to buy peer Lantheus Holdings in a deal worth up to $8 ‌billion, as the private equity-backed firm looks to expand its footprint in ‌the fast-growing sector. Radiopharmaceuticals, which …

Lantheus Holdings to Be Acquired for Initial $6.7 Billion

Lantheus Holdings is set to be acquired by Curium, a radiopharmaceutical company backed by CapVest Partners, for an initial $6.7 billion. Curium will pay $102.50 per share in cash, representing a 2.9% premium over Friday's closing price. This acquisition follows Lantheus's comprehensive evaluation of …

Curium Announces Definitive Agreement to Merge with Lantheus

Curium and Lantheus Holdings, Inc. have announced a definitive agreement for Curium to acquire Lantheus for up to $8.0 billion. The transaction involves a cash payment of $102.50 per share at closing, plus Contingent Value Rights of up to $12.00 per share tied to …

Curium to buy Bedford-based Lantheus in deal worth up to $8B

Curium is set to acquire Lantheus, a 70-year-old radiopharmaceutical company based in Massachusetts, for up to $8 billion. The acquisition highlights a significant transaction in the radiopharmaceutical field, though the future of Lantheus' Massachusetts workforce remains uncertain. The deal was reported by the Boston …

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus potential additional contingent value rights. The firm is examining whether Lantheus and its board …

Lantheus Holdings to Merge With Curium US Holdings in Up to $8 Billion Transaction Closing in H1 2027

Lantheus Holdings is set to merge with Curium US Holdings in a transaction valued at up to $8 billion, which is expected to close in the first half of 2027. This acquisition will see Curium expanding its radiopharma capabilities by integrating Lantheus, a company …